Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, presented first-in-human data for LFD-200, a novel subcutaneously administered ADC delivering a potent glucocorticoid directly to immune cells, at the European Congress of Rheumatology (EULAR) 2026 in London, UK, June 3-6, 2026.
Phase 1 data from healthy participants showed that LFD-200 was well tolerated and demonstrated dose-responsive anti-inflammatory activity with no impact on serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity. This finding is significant because it suggests LFD-200 may avoid the systemic side effects typically associated with glucocorticoid therapies, such as adrenal suppression and metabolic disturbances, while still providing anti-inflammatory benefits.
"We are encouraged by these initial Phase 1 results showing that LFD-200 has the potential to deliver the potent anti-inflammatory effects of glucocorticoids without the systemic toxicity that limits their use," said a Lifordi representative. The company is currently dosing patients with moderate to severe rheumatoid arthritis (RA) in the Phase 1 study, with data expected by year-end 2026.
The data were presented in a poster presentation at EULAR 2026, highlighting the potential of ADC technology in autoimmune diseases. LFD-200 is designed to target immune cells specifically, delivering a glucocorticoid payload directly to the site of inflammation. This approach aims to maximize efficacy while minimizing off-target effects, a key challenge in treating chronic inflammatory conditions.
Lifordi Immunotherapeutics is leveraging the success of ADCs in oncology to develop treatments for autoimmune and inflammatory disorders. Beyond LFD-200, the company is applying its novel drug delivery approach to other payloads, including antisense oligonucleotides, siRNA, and small molecules. The company is backed by prominent investors such as ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures.
The implications of these findings are substantial. If LFD-200 continues to demonstrate a favorable safety and efficacy profile in RA patients, it could offer a new treatment option that avoids the long-term complications of systemic glucocorticoids, such as osteoporosis, diabetes, and increased infection risk. Moreover, the subcutaneous administration route could improve patient convenience and adherence compared to intravenous therapies.
As the company moves forward with its Phase 1 trial in RA patients, the medical community awaits further data to confirm these promising early signals. The successful application of ADC technology to autoimmune diseases could open new avenues for targeted therapies in this space, potentially transforming the treatment landscape.
